Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 954

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 9
Chunk 954
---
25    3   -   78,750  12/13/26    17   -   31,500  12/11/29    1       92,400  4/5/31    8       92,400  4/5/31    13   -   13,300  3/28/32    13       7,035  1/30/33 Michael Thornton  -   -   159,250  5/12/25 Chief Technology Officer  8   -   175,000  5/12/25    3   -   78,750  12/13/26    16   -   31,500  12/11/29    1       92,400  4/5/31    8       92,400  4/5/31    12   7 (3)  13,300  3/28/32    12   26 (4)  7,035  1/30/33 Richard Jacroux  -   -   -   - Chief Financial Officer                Irina Pestrikova  -  -(5)   78,050  2/5/31 Former Senior Director, Finance (until August 8, 2024)  2   -   73,850  6/18/31    -   -   24,500  10/27/30    -   1 (3)  13,300  3/28/32    1   3 (4)  7,035  1/30/33 

(1)Represents unvested portion of stock option award which vests in three equal annual installments beginning on April 5, 2022.(2)Represents unvested portion of stock option award which vests as follows: (i) 25% vests upon the Company’s earning $5 million or more of revenue with a gross margin of 10% or greater, (ii) 25% vests upon the Company’s earning $10 million or more of revenue with a gross margin of 35% or greater, (iii)